Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Natera, Inc.
  6. News
  7. Summary
    NTRA   US6323071042

NATERA, INC.

(NTRA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Restricted Stock Units of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2021.

09/20/2021 EDT

Certain Restricted Stock Units of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2021. These Restricted Stock Units will be under lockup for 61 days starting from 21-JUL-2021 to 20-SEP-2021. Details: The company’s directors and executive officers, during the period ending 60 days after the date of this prospectus, (the "restricted period"), have agreed that, without the prior written consent of Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC on behalf of the underwriters, they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or publicly disclose the intention to engage in any such transaction; or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock.


© S&P Capital IQ 2021
All news about NATERA, INC.
10/18NATERA : Expands Organ Health Business With Commercial Launch of the Prospera™ Lung ..
PR
10/18Natera, Inc. Expands Organ Health Business With Commercial Launch of the Prospera Lung ..
CI
10/11NATERA : Announces New Publication Validating Signatera® Velocity Metric to Improve Cancer..
PR
10/11Natera, Inc. Announces New Publication Validating Signatera® Velocity Metric to Improve..
CI
10/06INSIDER SELL : Natera
MT
10/06Natera Announces Completion of the Largest Prospective Validation Study of a Commercial..
CI
09/30INSIDER SELL : Natera
MT
09/30VOLPARA HEALTH TECHNOLOGIES : Natera Enter Deal for Supply of Hereditary Cancer Test in US
MT
09/29Volpara Health Technologies Limited to Collaborate with Natera, Inc
CI
09/29NATERA : Court Rules in Natera's Favor Invalidating All of CareDx's Asserted Patents
PR
More news
Analyst Recommendations on NATERA, INC.
More recommendations
Financials (USD)
Sales 2021 615 M - -
Net income 2021 -416 M - -
Net cash 2021 591 M - -
P/E ratio 2021 -24,3x
Yield 2021 -
Capitalization 10 544 M 10 544 M -
EV / Sales 2021 16,2x
EV / Sales 2022 13,5x
Nbr of Employees 1 815
Free-Float 96,3%
Chart NATERA, INC.
Duration : Period :
Natera, Inc. Technical Analysis Chart | NTRA | US6323071042 | MarketScreener
Technical analysis trends NATERA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 112,43 $
Average target price 150,11 $
Spread / Average Target 33,5%
EPS Revisions
Managers and Directors
Stephen Chapman President, Chief Executive Officer & Director
Michael Burkes Brophy Chief Financial Officer
Matthew Rabinowitz Executive Chairman
Paul R. Billings Chief Medical Officer & Senior VP-Medical Affairs
Eric A. Evans Chief Scientific Officer
Sector and Competitors